A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

Despite the development of a number of efficacious kinase inhibitors, the strategies for rational design of these compounds have been limited by target promiscuity. In an effort to better understand the nature of kinase inhibition across the kinome, especially as it relates to off-target effects, we screened a well-defined collection of kinase inhibitors using biochemical assays for inhibitory activity against 234 active human kinases and kinase complexes, representing all branches of the kinome tree. For our study we employed 158 small molecules initially identified in the literature as potent and specific inhibitors of kinases important as therapeutic targets and/or signal transduction regulators. Hierarchical clustering of these benchmark kinase inhibitors on the basis of their kinome activity profiles illustrates how they relate to chemical structure similarities and provides new insights into inhibitor specificity and potential applications for probing new targets. Using this broad dataset, we provide a framework for assessing polypharmacology. We not only discover likely off-target inhibitor activities and recommend specific inhibitors for existing targets, but also identify potential new uses for known small molecules.

[1]  J. Hamilton CSF‐1 signal transduction , 1997, Journal of leukocyte biology.

[2]  Y. Hashimoto,et al.  Polyenylidene thiazolidinedione derivatives with retinoidal activities. , 1997, Chemical & pharmaceutical bulletin.

[3]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[4]  J. Rubin,et al.  Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a–dependent neurite outgrowth , 2011, The Journal of cell biology.

[5]  R. Wenger,et al.  Substrate preference and phosphatidylinositol monophosphate inhibition of the catalytic domain of the Per‐Arnt‐Sim domain kinase PASKIN , 2011, The FEBS journal.

[6]  Gillian H. Little,et al.  Critical Role of Nuclear Calcium/Calmodulin-dependent Protein Kinase IIδB in Cardiomyocyte Survival in Cardiomyopathy* , 2009, The Journal of Biological Chemistry.

[7]  K. Kaibuchi,et al.  Regulation and functions of Rho-associated kinase. , 2000, Experimental cell research.

[8]  Y. Miki,et al.  DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. , 2012, The Journal of clinical investigation.

[9]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[10]  J. Boehm,et al.  Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. , 1997, Bioorganic & medicinal chemistry.

[11]  J. R. Daum,et al.  Histone H3 Thr-3 Phosphorylation by Haspin Positions Aurora B at Centromeres in Mitosis , 2010, Science.

[12]  Eric O Long,et al.  β2 Integrin Induces TCRζ–Syk–Phospholipase C-γ Phosphorylation and Paxillin-Dependent Granule Polarization in Human NK Cells , 2011, The Journal of Immunology.

[13]  Jung Kyoon Choi,et al.  Identification of DNA methylation changes associated with human gastric cancer , 2011, BMC Medical Genomics.

[14]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[15]  Pascal Furet,et al.  Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. , 2006, Journal of medicinal chemistry.

[16]  H. Gram,et al.  Negative Regulation of Protein Translation by Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 , 2001, Molecular and Cellular Biology.

[17]  K. Shokat,et al.  The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. , 2011, Annual review of biochemistry.

[18]  J. Ham,et al.  c-Jun and the transcriptional control of neuronal apoptosis. , 2000, Biochemical pharmacology.

[19]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[20]  Y. Hashimoto,et al.  Polyenylidine Thiazolidine Derivatives with Retinoidal Activities , 1997 .

[21]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[22]  J. Rutter,et al.  PAS Kinase Promotes Cell Survival and Growth Through Activation of Rho1 , 2012, Science Signaling.

[23]  Jane Endicott,et al.  Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. , 2003, Journal of medicinal chemistry.

[24]  S. Desiderio,et al.  Mimicry of Pre–B Cell Receptor Signaling by Activation of the Tyrosine Kinase Blk , 2003, The Journal of experimental medicine.

[25]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[26]  M. Esteller,et al.  Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin , 2011, Oncogene.

[27]  N. Walker,et al.  Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. , 2006, Bioorganic & medicinal chemistry letters.

[28]  R. Wenger,et al.  Substrate preference and phosphatidylinositol monophosphate inhibition of the catalytic domain of the PAS kinase PASKIN , 2011 .

[29]  S. Nishikawa,et al.  A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.

[30]  N. Gray,et al.  In situ kinase profiling reveals functionally relevant properties of native kinases. , 2011, Chemistry & biology.

[31]  S. Frye Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.

[32]  J. Cox,et al.  Proteomics strategy for quantitative protein interaction profiling in cell extracts , 2009, Nature Methods.

[33]  H. D. de Koning,et al.  Pharmacological Validation of Trypanosoma brucei Phosphodiesterases as Novel Drug Targets , 2012, The Journal of infectious diseases.

[34]  L. Galluzzi,et al.  Selective killing of p53-deficient cancer cells by SP600125 , 2012, EMBO molecular medicine.

[35]  F. Berger,et al.  Inhibition of c-Jun N-terminal kinase by SP600125: a cDNA microarray analysis. , 2010, Cancer genomics & proteomics.

[36]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[38]  Mauro Riccaboni,et al.  Spleen tyrosine kinases: biology, therapeutic targets and drugs. , 2010, Drug discovery today.

[39]  K. Nishio,et al.  Mitogen‐activated protein kinase phosphatase‐1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor‐tyrosine kinase , 2009, The FEBS journal.

[40]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[41]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[42]  X. P. Liu,et al.  Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Rutter,et al.  PAS kinase: integrating nutrient sensing with nutrient partitioning. , 2012, Seminars in Cell and Developmental Biology.

[44]  A. Kieser,et al.  The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. , 2008, Virology.

[45]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[46]  D. Payan,et al.  Discovery and development of spleen tyrosine kinase (SYK) inhibitors. , 2012, Journal of medicinal chemistry.

[47]  A. Itai,et al.  Novel thiazolidinedione derivatives with retinoid synergistic activity. , 1998, Biological & pharmaceutical bulletin.

[48]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[49]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[50]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[51]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[52]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[53]  S. Bonner-Weir,et al.  Mutations at the BLK locus linked to maturity onset diabetes of the young and β-cell dysfunction , 2009, Proceedings of the National Academy of Sciences.

[54]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[55]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[56]  Steven Finkbeiner,et al.  A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model , 2010, Proceedings of the National Academy of Sciences.

[57]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[58]  Joost C. M. Uitdehaag,et al.  A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets , 2012, British journal of pharmacology.

[59]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[60]  S. Knapp,et al.  The (un)targeted cancer kinome. , 2010, Nature chemical biology.

[61]  Jens Timmer,et al.  Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. , 2009, Cancer research.

[62]  S. Homma,et al.  Inhibition of c-Jun-N-terminal Kinase Increases Cardiac Peroxisome Proliferator-activated Receptor α Expression and Fatty Acid Oxidation and Prevents Lipopolysaccharide-induced Heart Dysfunction* , 2011, The Journal of Biological Chemistry.

[63]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[64]  P. Cohen Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. , 2009, The Biochemical journal.

[65]  N. Munshi,et al.  JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* , 2003, The Journal of Biological Chemistry.

[66]  Yanli Wang,et al.  Identifying Compound-Target Associations by Combining Bioactivity Profile Similarity Search and Public Databases Mining , 2011, J. Chem. Inf. Model..